OSU-ERβ-12: a promising pre-clinical candidate selective estrogen receptor beta agonist

Area of Science:

• Pharmacology
• Endocrinology
• Drug Discovery

Background:

• Estrogen receptor beta (ERβ) is a key therapeutic target for inflammatory diseases, fibrosis, and cancers.
• Selective targeting of ERβ over estrogen receptor alpha (ERα) remains a significant challenge in drug development.

Purpose of the Study:

• To compare the pharmacokinetic and functional profiles of a novel ERβ agonist, OSU-ERβ-12, with a clinical comparator, erteberel (LY500307).
• To evaluate the selectivity, stability, and off-target interactions of OSU-ERβ-12.

Main Methods:

• Development of OSU-ERβ-12, a novel carborane-based ERβ agonist with >100-fold selectivity for ERβ over ERα.
• Pharmacokinetic profiling and functional activity assessment in multiple pre-clinical model systems.
• In vitro assays for human liver microsome stability and off-target interactions (CYP, hERG).

Main Results:

• OSU-ERβ-12 demonstrated superior pharmacokinetics in pre-clinical models compared to LY500307.
• OSU-ERβ-12 maintained high ERβ selectivity and exhibited excellent human liver microsome stability.
• Negligible interactions with CYP enzymes and hERG channels were observed for OSU-ERβ-12, indicating a favorable safety profile.

Conclusions:

• OSU-ERβ-12 is a potent and highly selective ERβ agonist with improved pharmacokinetic properties.
• Its favorable safety profile and enhanced efficacy suggest OSU-ERβ-12 warrants further investigation as a therapeutic agent.